Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of 8- Versus 12-week Sofosbuvir-ravidasvir Treatment of Non-cirrhotic Chronic Hepatitis C Patients: An Open-label, Randomized, Multicenter Study in Malaysia

NCT04885855 is registered in ClinicalTrials.gov with Muhammad Radzi Abu Hassan as lead sponsor.

NCT NCT04885855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04885855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of 8- Versus 12-week Sofosbuvir-ravidasvir Treatment of Non-cirrhotic Chronic Hepatitis C Patients: An Open-label, Randomized, Multicenter Study in Malaysia
Lead sponsor
Muhammad Radzi Abu Hassan
Phase
Phase 2/3
Overall status
Completed
Start date
March 23, 2021
Completion date
March 15, 2024
Enrollment
322 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c